Business
CollPlant to Present at Fall Harvest - Best Ideas from the Buy-Side on October 5, 2021
REHOVOT, Israel, Sept. 30, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative
About this update from Collplant Biotechnologies Ltd.
[{"type":"text","content":"REHOVOT, Israel, Sept. 30, 2021 /PRNewswire/ -- CollPlant Biotechnologies (NASDAQ: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products for tissue regeneration and organ manufacturing, has been invited to present at the Fall Harvest – Best Ideas from the Buy-Side conference, which is being held virtually on October 5th – 8th, 2021. Mr. Yehiel Tal, CollPlant's Chief Executive Officer, will present at the conference. \n\n \n \n \n \n \n \n\n \nCollPlant is scheduled to present on October 5, 2021 at 8:30 AM-8:55 AM ET. Management will be available for one-on-one meetings to be held throughout the conference. The presentation will be webcast live and available for replay at https://www.webcaster4.com/Webcast/Page/2800/42994 \nTo receive additional information, request an invitation or to schedule a one-on-one meeting, please email [email protected]. \nInvestors can register here. \nAbout the MicroCap Rodeo Summer Solstice Best Ideas ConferenceThe MicroCap Rodeo is back with its fourth \"Best Ideas\" conference. This conference is a virtual conference that brings you the top 35 best ideas from the buy side. Qualified institutional investors recommended each of the 35 companies represented as one of their best ideas. Those of you who attended the 2019 MicroCap Rodeo in Austin, Texas, know that we're focused on alpha.\nAbout CollPlant\nCollPlant is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, and medical aesthetics. The Company's products are based on its recombinant human collagen produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing, and are ushering in a new era in regenerative and aesthetic medicine. \nCollPlant recently entered a development and global commercialization agreement for dermal and soft tissue fillers with Allergan, an AbbVie company, the global leader in the dermal filler market. Later in 2021, CollPlant entered a strategic co-development agreement with 3D Systems for a 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures in combination with an implant.\nFor more information, visit http://www.collplant.com.\nSafe Harbor Statements\nTh...